Literature DB >> 22658527

Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies.

M Alvarez-Jimenez1, A Priede, S E Hetrick, S Bendall, E Killackey, A G Parker, P D McGorry, J F Gleeson.   

Abstract

BACKGROUND: Preventing relapse is an essential element of early intervention in psychosis, but relevant risk factors and precise relapse rates remain to be clarified. The aim of this study was to systematically compile and analyse risk factors for and rates of relapse in the early course of psychosis.
METHODS: Systematic review and meta-analysis of English and non-English language, peer-reviewed, longitudinal studies, with a minimum 12-month follow-up and at least 80% of participants diagnosed with a first episode of psychosis (FEP) that reported risk factors for relapse.
RESULTS: Of 153 potentially relevant articles, 29 were included in the study. Pooled prevalence of relapse of positive symptoms was 28% (range=12-47%), 43% (35-54%), 54% (40-63%) at 1, 1.5-2, and 3 years follow-up, in that order. A total of 109 predictors were analysed, with 24 being assessed in at least 3 studies. Of those, 20 predictors could be extracted for meta-analysis. Medication non-adherence, persistent substance use disorder, carers' critical comments (but not overall expressed emotion) and poorer premorbid adjustment, increased the risk for relapse 4-fold, 3-fold, 2.3-fold and 2.2-fold, respectively.
CONCLUSIONS: Clinical variables and general demographic variables have little impact on relapse rates. Conversely, non-adherence with medication, persistent substance use disorder, carers' criticism and poorer premorbid adjustment significantly increase the risk for relapse in FEP. Future studies need to address the methodological limitations of the extant research (e.g. definition of relapse), focus on the identification of protective factors and evaluate theoretically derived models of relapse.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22658527     DOI: 10.1016/j.schres.2012.05.007

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  111 in total

1.  Functional deterioration from the premorbid period to 2 years after the first episode of psychosis in early-onset psychosis.

Authors:  Ángel Del Rey-Mejías; David Fraguas; Covadonga M Díaz-Caneja; Laura Pina-Camacho; Josefina Castro-Fornieles; Inmaculada Baeza; Ana Espliego; Jessica Merchán-Naranjo; Ana González-Pinto; Elena de la Serna; Beatriz Payá; Montserrat Graell; Celso Arango; Mara Parellada
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-03-01       Impact factor: 4.785

2.  Expressed emotion and the course of schizophrenia in Pakistan.

Authors:  Sarosh Sadiq; Kausar Suhail; John Gleeson; Mario Alvarez-Jimenez
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2017-03-04       Impact factor: 4.328

3.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

4.  Family burden predicts functional outcome in the early course of schizophrenia beyond psychiatric symptoms and baseline functioning.

Authors:  Nicole R DeTore; Joseph Ventura; Kenneth L Subotnik; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2018-07-07       Impact factor: 4.939

Review 5.  Relapse risk assessment in early phase psychosis: the search for a reliable and valid tool.

Authors:  Phil Tibbo; Ashok Malla; Rahul Manchanda; Richard Williams; Ridha Joober
Journal:  Can J Psychiatry       Date:  2014-12       Impact factor: 4.356

6.  The revolving door of mental, neurological, and substance use disorders re-hospitalization in rural KwaZulu-Natal Province, South Africa.

Authors:  Andrew Tomita; Yoshan Moodley
Journal:  Afr Health Sci       Date:  2016-09       Impact factor: 0.927

Review 7.  The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.

Authors:  Marc De Hert; Jan Sermon; Paul Geerts; Kristof Vansteelandt; Joseph Peuskens; Johan Detraux
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

8.  Effectiveness of Family Intervention for Preventing Relapse in First-Episode Psychosis Until 24 Months of Follow-up: A Systematic Review With Meta-analysis of Randomized Controlled Trials.

Authors:  Miguel Camacho-Gomez; Pere Castellvi
Journal:  Schizophr Bull       Date:  2020-01-04       Impact factor: 9.306

9.  Family Functioning in First-Episode and Chronic Psychosis: The Role of Patient's Symptom Severity and Psychosocial Functioning.

Authors:  Katerina Koutra; Sofia Triliva; Theano Roumeliotaki; Maria Basta; Christos Lionis; Alexandros N Vgontzas
Journal:  Community Ment Health J       Date:  2015-08-19

10.  Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed.

Authors:  Margaret Haney; A Eden Evins
Journal:  Neuropsychopharmacology       Date:  2015-08-19       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.